FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.

FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.

Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.

News Market Reaction – FBLG

+12.07%

1 alert

+12.07% News Effect

On the day this news was published, FBLG gained 12.07%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. 

About FibroBiologics 

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

General Inquiries: 
info@fibrobiologics.com 

Investor Relations: 
Nic Johnson 
Russo Partners 
(212) 845-4242 
fibrobiologicsIR@russopr.com 

Media Contact: 
Liz Phillips 
Russo Partners 
(347) 956-7697 
Elizabeth.phillips@russopartnersllc.com 

FAQ

When is FibroBiologics (FBLG) participating in the 2024 Maxim Healthcare Virtual Summit?

FibroBiologics (FBLG) is participating in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

What is FibroBiologics' (FBLG) main focus in biotechnology?

FibroBiologics (FBLG) focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

How many patents does FibroBiologics (FBLG) hold?

FibroBiologics (FBLG) holds over 160 US and internationally issued patents and patents pending across various clinical pathways.

What clinical pathways does FibroBiologics (FBLG) research cover?

FibroBiologics (FBLG) research covers clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.

Who will represent FibroBiologics (FBLG) at the 2024 Maxim Healthcare Virtual Summit?

Pete O'Heeron, Chief Executive Officer of FibroBiologics (FBLG), will represent the company at the 2024 Maxim Healthcare Virtual Summit.